PO.MCB07.04 · 分子与细胞生物学
探究转录因子ERG与TGF-beta信号通路在宫颈癌细胞中的相互作用
Investigating the interplay of transcription factor, ERG, and TGF-beta signaling in cervical cancer cells
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
在健康细胞中,TGF-beta信号通路对细胞周期至关重要。该通路促进凋亡、抑制细胞增殖并刺激免疫细胞激活。然而在恶性细胞中,TGF-beta信号通路已被证明通过迁移和转移、免疫逃逸及血管生成驱动癌症增殖。随着癌症进展,TGF-beta信号通路的作用从抑制肿瘤转变为促进肿瘤。利用TCGA数据,我们鉴定出与TbetaRIII共表达的基因。在确定哪些基因具有最高相关性后,我们使用Enrichr进行通路分析。通路分析提示与ERG存在关联,促使我们假设ERG调控TbetaRIII及其他相关基因。ERG似乎与TGF-beta共有许多癌症行为,如宫颈癌中的增殖、侵袭和整体细胞存活。TCGA数据的Kaplan-Meier生存曲线支持在多种其他癌症中高ERG表达与生存率下降相关,就本研究范围而言特别是宫颈癌。然而,ERG在此背景下尚未被广泛研究。Western印迹分析证实了HeLa细胞中ERG的表达。功能实验表明,操纵HeLa细胞表达ERG敲低导致细胞迁移显著减少。向ERG敲低(shERG)的HeLa细胞中添加TGF-beta可部分恢复迁移,提示TGF-beta可能补偿ERG表达的缺失。为进一步探究ERG对TGF-beta的影响,我们使用了galunisertib(一种已知的TGF-beta信号通路抑制剂)。划痕实验分析显示,在对照HeLa细胞中,暴露于galunisertib时迁移率显著降低。在HeLa-shERG细胞中,迁移同样减少;然而galunisertib未能在HeLa-shERG细胞中产生同样的迁移减少模式,提示ERG和TGF-beta通路可能以某种方式趋同。HeLa-shERG显著降低了TGFbeta-I的表达,同时减少了SMAD2(一种在TGF-beta信号通路中发挥重要作用的转录因子)的激活。侵袭实验揭示了在操纵TGF-beta和ERG以测量转移时HeLa细胞穿越细胞外基质的能力。目前正在进行ChIP-seq以研究宫颈癌中TGFB信号通路与ERG在基因组上的占据之间可能的相互作用,并将与已被广泛研究的癌症中的ERG位点进行比较。总之,这些发现提示ERG至少部分通过调控TGF-beta信号通路促进宫颈癌细胞的迁移和侵袭。
查看英文原文 English abstract
In healthy cells, TGF-beta signaling is crucial to the cell cycle. The pathway promotes apoptosis, suppresses cellular proliferation, and stimulates immune cell activation. In malignant cells, however, TGF-beta signaling has been shown to drive the proliferation of cancer through migration and metastasis, immune evasion, and angiogenesis. The effects of TGF-beta signaling shift from tumor-suppressing to tumor-promoting as cancer progresses. Using TCGA data, we identified genes coexpressed with TbetaRIII. After determining which genes had the highest correlation, we used Enrichr to conduct pathway analysis. Pathway analysis indicated a relationship with ERG, leading us to hypothesize that ERG regulates TbetaRIII and other related genes. ERG seems to share many cancer behaviors with TGF-beta, such as proliferation, invasion, and overall cell survival in cervical cancer. Kaplan-Meier Survival plots of TCGA data support decreased survival rates with high ERG expression in several other cancers as well, for the scope of this study, cervical cancer specifically. However, ERG has not been extensively investigated in this context. Western Blot analysis confirmed the presence of ERG expression in HeLa cells. Functional assays demonstrated that manipulating HeLa cells to express a knockdown of ERG led to a significant decrease in cell migration. The addition of TGF-beta to HeLa cells with ERG knockdown (shERG) partially restores migration, suggesting that TGF-beta could potentially compensate for the loss of ERG expression. To further investigate the effects of ERG on TGF-beta, galunisertib, a known inhibitor of TGF-beta signaling, was used. Analysis of scratch assays showed that in control HeLa cells, migration rates significantly reduced when exposed to galunisertib. In HeLa-shERG cells, migration was reduced as well; however, galunisertib failed to have the same decreased migration pattern in HeLa-shERG cells, suggesting that ERG and TGF-beta pathways may converge in some way. HeLa-shERG significantly reduced the expression of TGFbeta-I as well as decreasing the activation of SMAD2, a transcription factor that plays a significant role in TGF-beta signaling. Invasion assays exposed HeLa cells' ability to travel throughout the extracellular matrix when manipulating TGF-beta and ERG to measure metastasis. ChIP-seq is being done to investigate the possible interactions between TGFB signaling and ERG occupancy on the genome in cervical cancer, which will be compared to ERG sites in extensively studied cancers. Together, these findings suggest that ERG promotes cervical cancer cell migration and invasion, at least in part by regulating TGF-beta signaling.
利益披露 Disclosure
K. M. Eidson, None..
H. M. Fitzgibbons, None..
L. J. Baker, None..
B. M. Greulich, None.